Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008

Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)

(2010) Melissa Kerkhof et al.   INTERNATIONAL JOURNAL OF CANCER

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

(2010) Jonas Hugosson et al.   LANCET ONCOLOGY

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

(2009) Pim J. van Leeuwen et al.   EUROPEAN JOURNAL OF CANCER

Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

(2009) Monique J. Roobol et al.   EUROPEAN UROLOGY

Mortality Results from a Randomized Prostate-Cancer Screening Trial

(2009) Gerald L. Andriole et al.   NEW ENGLAND JOURNAL OF MEDICINE

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0–10.0 ng/mL

(2008) Alexandre E. Pelzer et al.   BJU INTERNATIONAL

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

(2008) Georg Bartsch et al.   BJU INTERNATIONAL